A Theranostic Small-Molecule Prodrug Conjugate for Neuroendocrine Prostate Cancer
After androgen deprivation therapy, a significant number of prostate cancer cases progress with a therapy-resistant neuroendocrine phenotype (NEPC). This represents a challenge for diagnosis and treatment. Based on our previously reported design of theranostic small-molecule prodrug conjugates (T-SM...
Saved in:
Main Authors: | Paulina Gonzalez (Author), Sashi Debnath (Author), Yu-An Chen (Author), Elizabeth Hernandez (Author), Preeti Jha (Author), Marianna Dakanali (Author), Jer-Tsong Hsieh (Author), Xiankai Sun (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2023-02-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Synthesis and Evaluation of ePSMA-DM1: A New Theranostic Small-Molecule Drug Conjugate (T-SMDC) for Prostate Cancer
by: Erika Murce, et al.
Published: (2023) -
(Radio)Theranostic Patient Management in Oncology Exemplified by Neuroendocrine Neoplasms, Prostate Cancer, and Breast Cancer
by: Irina Velikyan
Published: (2020) -
Current Status of Radiopharmaceuticals for the Theranostics of Neuroendocrine Neoplasms
by: Melpomeni Fani, et al.
Published: (2017) -
Strategies for the development of stimuli-responsive small molecule prodrugs for cancer treatment
by: Yuxuan Tu, et al.
Published: (2024) -
Small cell-like change in prostatic adenocarcinoma and intraductallesions - neuroendocrine or not?
by: Daniel Abensur Athanazio, et al.
Published: (2022)